American Pharmacy

Journal of the American Pharmaceutical Association

INDEX TO VOLUME NS24 (1984)

Prepared by Sydney Schultz, MLS

The annual index is a single alphabetical listing of names and subjects. Numbers refer to the serial paging found with the title line at the bottom of each journal page. Pages contained in each issue are shown in the accompanying box. Books reviewed are listed by title under the entry "Book Reviews." Nonproprietary drug names are used in most cases.

Issue	Pages	Issue	Pages
January*	1–52	July***	393–488
February	53–100	August †	489–564
March	101–164	September	565–628
April	165–228	October ††	629–704
May**	229–320	November	705–772
June	321–392	December	773–868

*Contains special section, "APhA's 131st Annual Meeting," following page 20.
**Contains special section, "A Life Dedicated to Pharmacy: An Appreciation of William S. Apple," following page 264.
***Contains "Montreal [1984 Annual Meeting] Highlights," pages 431–469.
†Contains special section, "The American Institute of Pharmacy: 50th Anniversary," following page 516.
††Contains special section, "APhA '85," following page 660.

A

Academy of Pharmaceutical Management, 236, 442
Academy of Pharmaceutical Sciences, 438–439
Academy of Pharmacy Practice, 236, 437–438, 496, 636
Accidents, automobile, and psychoactive drugs, 726
Acetaminophen, 13, 104, 142, 233, 243–245, 250, 296, 414, 652, 758–761
Acetazolamide, 140
Acetohexamide, 824–837
Acetohydroxamic acid, 128–129
Acquired immune deficiency syndrome (AIDS), 507, 611
Actifed, and hallucinations in children, 647
Acupuncture, 299
Acutrim, NDA for, 720
Acyclovir, 412, 591–595
Adams, Gene, 148
Adams, Stewart, 404
Adkinson, N. Franklin, 67
Adrenergic inhibitors, 373–376
Adriamycin, 582
Adult-onset diabetes, 415
Adverse drug reactions, *book*, 704
  reporting systems for, 793–794, 795–796
Aerosolized zirconium, 8
AIDS, 507, 611
Albuterol, 659
Alcohol abuse, 98, 181, 227
Alcohol consumption, and drug interactions, 288, 740
  and hypertension, 370
Allergy medications, 246, 499, 650, 659
Allopurinol, 288
Alpha-1 antitrypsin, 248
Alprostadil, 410
AMA Drug Evaluations, 4, 5, 738, 739, 759
AMA/NET Information Services, 42
Amantadine, 503–504
American Academy of Dermatology, 795–796
American Academy of Family Physicians, 236, 573
American Academy of Pediatrics, 142, 145
American Association of Colleges of Pharmacy, 428, 742–744, 764, 767
American Cancer Society, 388, 389
American College of Obstetrics and Gynecology, 646
American Council on Pharmaceutical Education, 117–119, 453, 742, 768
American Dental Association, 182, 236, 331, 585
American Diabetes Association, 415
American Heart Association, 66
American Institute of Pharmacy, 573, 637–639
  See also August Special Section.
American Medical Association, 42, 64, 75, 715, 753
American Pharmaceutical Association (APhA), annual review (1984), 814–823
  headquarters building, 573, 637–639; *see also* August Special Section.
  patient education activities, 65, 110, 111, 368, 546, 575, 645, 710
  professional liaison, 64, 182, 236, 328, 445, 453, 573, 710
  receives Burroughs Wellcome award funds, 804–805
  staff reorganization, 710
  trustees, board of, 6, 59, 109, 256, 329–330, 537
American Pharmaceutical Association Annual Meeting report, 431–469
  address of Speaker Anderson, 447–449
  address of President Bectel, 444–446
  address of Chairman Carlin, 440–443
  announcements (1984), 154–162, 224–226; *see also* January Special Section.
  announcements (1985), 515–516, 733; 844–857; *see also* October Special Section.
  awards and honors, 436–439
  bylaws changes, 448
  educational affairs, 458–460
  financial report, 450
  highlights, 431–435
  House of Delegates actions, 451–469
  membership study, 445
  professional affairs, 454–457
  public affairs, 461–464
  scientific affairs, 465–469
American Pharmaceutical Association positions on:
  ACPE accreditation standards, 453
  ANDAs, 328, 398, 453, 465–466
  cigarette smoking, 211

American Pharmacy

Journal of the American Pharmaceutical Association

INDEX TO VOLUME NS24 (1984)

Prepared by Sydney Schultz, MLS

The annual index is a single alphabetical listing of names and subjects. Numbers refer to the serial paging found with the title line at the bottom of each journal page. Pages contained in each issue are shown in the accompanying box. Books reviewed are listed by title under the entry "Book Reviews." Nonproprietary drug names are used in most cases.

Issue	Pages	Issue	Pages
January*	1–52	July***	393–488
February	53–100	August †	489–564
March	101–164	September	565–628
April	165–228	October ††	629–704
May**	229–320	November	705–772
June	321–392	December	773–868

*Contains special section, "APhA's 131st Annual Meeting," following page 20.
**Contains special section, "A Life Dedicated to Pharmacy: An Appreciation of William S. Apple," following page 264.
***Contains "Montreal [1984 Annual Meeting] Highlights," pages 431–469.
†Contains special section, "The American Institute of Pharmacy: 50th Anniversary," following page 516.
††Contains special section, "APhA '85," following page 660.

A

Academy of Pharmaceutical Management, 236, 442
Academy of Pharmaceutical Sciences, 438–439
Academy of Pharmacy Practice, 236, 437–438, 496, 636
Accidents, automobile, and psychoactive drugs, 726
Acetaminophen, 13, 104, 142, 233, 243–245, 250, 296, 414, 652, 758–761
Acetazolamide, 140
Acetohexamide, 824–837
Acetohydroxamic acid, 128–129
Acquired immune deficiency syndrome (AIDS), 507, 611
Actifed, and hallucinations in children, 647
Acupuncture, 299
Acutrim, NDA for, 720
Acyclovir, 412, 591–595
Adams, Gene, 148
Adams, Stewart, 404
Adkinson, N. Franklin, 67
Adrenergic inhibitors, 373–376
Adriamycin, 582
Adult-onset diabetes, 415
Adverse drug reactions, *book*, 704
  reporting systems for, 793–794, 795–796
Aerosolized zirconium, 8
AIDS, 507, 611
Albuterol, 659
Alcohol abuse, 98, 181, 227
Alcohol consumption, and drug interactions, 288, 740
  and hypertension, 370
Allergy medications, 246, 499, 650, 659
Allopurinol, 288
Alpha-1 antitrypsin, 248
Alprostadil, 410
AMA Drug Evaluations, 4, 5, 738, 739, 759
AMA/NET Information Services, 42
Amantadine, 503–504
American Academy of Dermatology, 795–796
American Academy of Family Physicians, 236, 573
American Academy of Pediatrics, 142, 145
American Association of Colleges of Pharmacy, 428, 742–744, 764, 767
American Cancer Society, 388, 389
American College of Obstetrics and Gynecology, 646
American Council on Pharmaceutical Education, 117–119, 453, 742, 768
American Dental Association, 182, 236, 331, 585
American Diabetes Association, 415
American Heart Association, 66
American Institute of Pharmacy, 573, 637–639
  See also August Special Section.
American Medical Association, 42, 64, 75, 715, 753
American Pharmaceutical Association (APhA), annual review (1984), 814–823
  headquarters building, 573, 637–639; *see also* August Special Section.
  patient education activities, 65, 110, 111, 368, 546, 575, 645, 710
  professional liaison, 64, 182, 236, 328, 445, 453, 573, 710
  receives Burroughs Wellcome award funds, 804–805
  staff reorganization, 710
  trustees, board of, 6, 59, 109, 256, 329–330, 537
American Pharmaceutical Association Annual Meeting report, 431–469
  address of Speaker Anderson, 447–449
  address of President Bectel, 444–446
  address of Chairman Carlin, 440–443
  announcements (1984), 154–162, 224–226; *see also* January Special Section.
  announcements (1985), 515–516, 733; 844–857; *see also* October Special Section.
  awards and honors, 436–439
  bylaws changes, 448
  educational affairs, 458–460
  financial report, 450
  highlights, 431–435
  House of Delegates actions, 451–469
  membership study, 445
  professional affairs, 454–457
  public affairs, 461–464
  scientific affairs, 465–469
American Pharmaceutical Association positions on:
  ACPE accreditation standards, 453
  ANDAs, 328, 398, 453, 465–466
  cigarette smoking, 211

community pharmacy residencies, 452, 459–460, 808–809
dispensing by nonpharmacists, 452, 456–457
draft registration for women professionals, 452, 462–463
drug diversion, 328, 496, 710
drug pricing, 453, 562–564
education, 452, 458–459
FDA administrative detention, 452, 463–464
freedom of scientific information, 453, 467–468
heroin, 237, 715
human organ acquisition, 453, 466–467
impaired pharmacists, 496
labeling, 402–403, 405, 446
MAC, 446
methaqualone, 12
mobile pharmacies, 452, 455–456
patent term bill, 328, 398
Pharmaceutical Centers, 83–84
pharmacists in advertisements, 452, 461–462
pharmacy crime, 236, 331, 398, 446, 636, 729–732
pharmacy practice, 453
potassium iodide for nuclear accidents, 453, 468–469
reimbursement, 264, 328, 398, 401, 446, 453, 496, 543
Reye-aspirin link, 143, 145
Rx-OTC switch, 86–90, 185–186, 452, 454–455
taxation of health benefits, 464
third-party programs, 398, 401, 453, 496
American Pharmaceutical Association Foundation, 398, 438–439
American Pharmacy, 122
American Society of Hospital Pharmacists, 742, 743, 764
American Veterinary Medical Association, 236, 331
Amerson, Ann B., 70
Amidon, Gordon L., 438
Amikacin, 125
Amiloride, 374, 376
Aminoglycoside derivatives, 125–127
Amitryptyline, 298, 364, 408, 511, 726
Ammonium chloride, 740
Amoxicillin, 408
Amoxicillin-potassium clavulanate, 403
Ampicillin, 408
Amrinone, 728
Anagelsic nephropathy, 243–245
Analgesics, 8, 237–239, 250, 294–299, 414, 758–761
cost and sales data, 409, 499
See also Nonsteroidal anti-inflammatory drugs (NSAIDs).
ANDAs/NDAs, 328, 342, 398, 405, 453, 465–466, 502, 553, 573, 574, 576, 580, 636, 720
Anderson, Lowell J., 451, 743, 747
"Adapting to the New World of Pharmacy Economics," 425–428
"Strength and Credibility" [annual meeting address], 447–449
Anderson, Roger, "The Incontinent Patient: A Roundtable Discussion," 351–360
Anesthetics, 135, 299
Angina, 338, 412, 569, 581, 614, 659
Angiotensin-converting enzyme inhibitors, 374, 375, 377
Anslinger, Harry J., 58
Antacids, 712, 778–779
Anti-acne drugs, 507, 586
Anti-anxiety drugs, 115, 726
Anti-arthritics, 13, 233, 478–486, 584, 720, 728, 760–761
cost data, 409
Antibiotics, 61, 123–127, 403, 506
Anticancer drugs, 14–15, 69, 131, 176–178, 342, 350, 403, 582, 613
for arthritis, 486, 584
Anticlotting drugs, 614
Anticonvulsants, 194–202
Antidepressants, 409, 511–514, 612, 726
for pain management, 298
Antidiabetics, 403, 409. 415–416
Antidiarrheal drugs, 806
Antifungals, 126, 128, 660
Antihistamines, 246, 735, 738–739
Antihypertensives, 131–132, 368–377, 614, 650, 728, 806
Anti-infectives, 409
Anti-inflammatory drugs, 13, 614, 760–761
See also Nonsteroidal anti-inflammatory drugs (NSAIDs).
Antimalarials, for arthritis, 483
Antimicrobials, 235–236, 507
Antinausea drugs, 403
Antiplaque toothpastes, 585
Antipsychotics, 514, 802
Antipyretics, 243–245, 758–761
Antipyrine, 250, 761, 801
Antischistosomals, 128
Antismoking products and programs, 122, 210–212
Antispasmodics, 409
Antisubstitution, *See* Drug product selection.
Antitussives, 409, 499, 507, 735, 740
Anti-ulcer drugs, 137–138
Antivirals, 503–504
Aphrodisiac drugs, 722
Appel, Stanley, 611
Appetite suppressants. *See* Diet products.
Apple, William S., 19, 64, 70, 145, 185, 329, 428, 431, 435, 440, 443, 444, 538
eulogy and tributes, 55–58, 431
memorials, 109, 407, 443, 516
See also May Special Section.
Araujo, Oscar E., "Taking the Sizzle Out of the Sun," 362–366
Arthritis, 13, 233, 473–486, 584, 714, 720, 760–761
Arthritis Advisory Committee, 404, 714
Arthritis Foundation, 473
Artificial intelligence, 686
Artificial sweeteners, 655
Ascione, Frank J., 777
Aspirin, 67, 104, 243–245, 250, 363, 404, 414, 478–479, 481, 726, 728, 758–761
and Reye syndrome, 141–145, 789
Asthma, 285–293, 499, 509, 614, 659, 728
Atenolol, 373, 374, 376, 410, 581, 728
Athlete's foot, 126
Atracurium besylate, 136–137
Atropine, 408, 737, 738
Attitudes. *See* Consumer attitudes.
Avery, Oswald, 609
Awards and honors, 16, 122, 436–439, 804–805
Azathioprine, 486, 584

B

Bachman, Robert M., 168
Bacon, William R., "Adopt an Orphan Disease: Hemochromatosis," 622–623
Bacterial meningitis, 338
Bailey, J. M., 145
Ball, John R., "Collaboration in High Blood Pressure Control," 810–812
Baptista, Richard J., "Theophylline Pharmacotherapy," 285–293
Bargmann, Eve, 793–794
Barker, Kenneth N., 103
"Pharmacy Practice and the Future," 38–40
Barnes, Sandy, 759
Bascomb, Stuart L., 70
Beardsley, Robert S., 65
Beaver, William, 414
Becker, Allan, 509
Becker, Marshall, 252
Bectel, Maurice Q., 6, 57, 59, 109, 236, 237, 240, 328–331, 398, 401, 405, 431, 433, 435, 440, 450, 451, 573, 715
"Improving Patient Compliance," 546–548
"The Rx-OTC Switch: Good for Pharmacy," 184–187
"Weathering Stormy Seas" [Annual Meeting address], 444–446
"What's Good for the Patient is Good for Pharmacy," 18–19
Beechwood creosote, 740
Beekman, Bruce, 658
Behaviorial therapy, 210, 299, 371
Behm, Harriet L., 743, 747
Beling, Stephanie, 175
Bell, Joanne, 180
Belladona, 737, 738
Bendroflumethiazide, 374
Benzocaine, 363
Benzodiazepines, 11–13, 200, 587, 726
Benzithiazide, 374
Bepridil, 806
Bess, Gary, 803
Beta blockers, 338, 373, 374, 376, 728
Beta-lactam inhibitors, 403
Betamethasone diproprionate, 660
Betts, Robert, 337
Bewley, Peter, 790–791
Bhansali, K. G., 633
Billingsley, Len A., 396
Biocompatible microspheres drug delivery systems, 616
Biodegradable polymer drug delivery systems, 615
Biofeedback, 299
Biological equivalents, *definition*, 64
Biopharmaceutics, *book*, 558–559
Biotechnology. *See* Genetic engineering technology.
Bipolar mood disorder, 511–514
Birth control products, 140, 180, 408, 409, 422, 498, 584
Bisno, Allan L., 66
Black patients, 253
response to diuretics, 373
Bladder control problems, 351–360
Blevins, Julia, 254
Bliley, Thomas J., 331
Blockstein, William L., 743
"Consensus from a 'Microcosm': An Interview with William L. Blockstein," 744–751
Blood pressure, high. *See* Hypertension.
Blood pressure screening by pharmacists, 674–676, 681
Blood protein Factor VIII, for hemophiliacs, 612
Blue Cross/Blue Shield plans, 188–191
Body weight, and blood pressure, 370
Bohach, Carol, 632
Bohn, Rod, 568
Bok, Sisella, 5
Bolger, Robert J., 636, 639, 730, 732
Bolli, Geremia, 510
Bone loss. *See* Osteoporosis.
Bone marrow transplants, 613
Book reviews:
American Hospital Formulary Service, Drug Information [1984], 227
Biopharmaceutics and Drug Interactions, 3rd edition, 558–559
Commonalities in Substance Abuse and Habitual Behavior, 227
Handbook on Drug and Alcohol Abuse, 2nd edition, 98
Handbook on Injectable Drugs, 3rd edition, 99
Managing Computer Systems: Pharmacy and Other Hospital Departments, 98
Medications and the Elderly: A Guide for Promoting Proper Use, 558
Mill's Pharmacy State Board Review, 30th edition, 227
Pharmacist Role in Disease Prevention and Health Promotion, 558
Pharmacy Law and Ethics, 3rd edition, 318
Side Effects of Drugs, Annual 8 [1984], 704
USAN and the USP Dictionary of Drug Names [USAN 1984], 50
Your First Business Computer, 98
Boothe, Clayton D., "Medicare's Prospective Payment System," 258–264
Bootman, J. Lyle, "Women In Pharmacy Management: Why Not?" 214–219
Bowles, Grover C., 55, 109
" 'A Passion for the Profession of Pharmacy': Eulogy for William S. Apple," 57–58
Boyd, Eddie L., 70, 777
Boyd, Robert, 475
Boyer, Herbert, 612
Braden, Larry L., 401
Brands, Allen J., 6
Brandt, Edward M., Jr., 65, 238, 239, 507
Brantingham, Charles, 658
Breast feeding, contraindicated drugs, 61, 323, 415–416, 483, 486
Brenner, O. C., 216
Brewer, George, 116
Brodie, Donald C., 77, 80, 325, 326
Brompheniramine, 738
Bronchial asthma, 285–293, 509, 728
Bronchial therapy, cost data, 409
See also Cough medications.
Brown, Charles, 148
Brown, Jeffrey L., 403
Brown, R. D., 142
Brownlee, M., 826
Brusadin, Rinaldo A. (Ron), 443, 496, 603–605
Bufexamac, 248

Bumetanide, 133–134, 374, 376
Buprenorphine, 298
Burroughs Wellcome Pharmacy Education Program awards, 16, 804–805
Bush, Patricia, 5
Butler, Leona, 190
Butorphanol tartrate, 298

C

Cacek, Tim, 708
Caffeine, 10, 250, 414, 509
Calcium blockers, 177–178, 374, 377, 806
Calcium deficiency, 419, 422, 588, 646, 718
Calendar of professional meetings, 50, 319, 557, 770
California Pharmacists Association, 107–108, 190
Camerini-Davalos, R. A., 249, 250
Campbell, R. Keith, "Treating Diabetes in the 1980s and Beyond," 824–837
Camphorated oil, 8
Canadian Association of Pharmacy Students and Interns, 764
Cancer, breast, 176–177, 338, 582, 584
  colorectal, 654–655
  endometrial, 422
  pain management in, 122, 237–239, 294–299, 508
  squamous cell, 14
  testicular, 131
  See also Anticancer drugs; Antinausea drugs; Carcinogens.
Candidiasis, cutaneous, 126
  oral, 140, 492
Capitation reimbursement, 263–264, 426
Caplow, Theodore, 254
Captopril, 374, 377, 610
Carbamazepine, 194, 199, 514
Carcinogens, 798–800
Carcinogens, in foods, 15, 655
Cardiovascular disease, 114–115, 122, 140, 370, 373, 614, 728
  See also Angina.
Cardiovascular drugs, cost data, 409
Career opportunities, 46, 302–306, 492, 762, 763, 767–768
Carlin, Herbert S., 6, 109, 236, 329, 407, 431, 433, 435, 537, 556, 573, 637, 710
  "Opportunities for Healing" [Annual Meeting address], 440–443
Catizone, Carmen, 233
  "Office-Based Pharmacy In the United States: The Development of a Practice Alternative," 76–84
Cefamandole, 125
Cefonicid, 403
Cefoperazone, 125
Cefotaxime, 123, 125, 410, 652
Cefoxitin, 125, 652
Ceftizoxime sodium, 123, 125, 338
Cefuroxime, 123, 125, 652
Centers for Disease Control (CDC), 141, 142, 180, 503–504, 584, 652
Cephalosporin derivatives, 123–125, 127, 403
Certification. *See* Professional licensure and certification.
Cetron, Marvin J., 433, 435
  "Encounters With the Future: An Interview with Marvin J. Cetron," 33–37
Chabner, Bruce, 176, 177
Chafetz, Lester, 439
Check, William A., "New Drugs and Drug Delivery Systems in the Year 2000," 608–620
Chemical carcinogens, 798–800
Chemical equivalents, *definition*, 64
Chenodeoxycholic acid, 138
Chickenpox, 142
Chenodiol, 138–139
Child-resistant packaging, 61
Children, antidiarrheal for, 806
  aspirin-Reye syndrome link in, 141–145, 789
  ceftizoxime for, 338
  influenza immunization for, 503–504
  pain management in, 299
  patient information on, 676–678
  sleep disorders in, 13
  sulfonamides for, 506
  theophylline for, 289
  vitamins for, 344, 350
Chlamydial throat infections, 66
Chlorazepate, 194, 200
Chlorhexidine, 336
Chloroquine, 483
Chlorothiazide sodium, 364, 374
Chlorpheniramine, 246, 650, 738
Chlorpromazine, 298, 364
Chlorpropamide, 364, 728, 788–789, 824–837
Chlorthalidone, 374, 728
Cholesterol, 114–115, 585
Cholestyramine, 114
Ciabattoni, G., 339, 350
Ciccone, Patrick E., 790–792
Ciclopirox olamine, 126, 128
Cigarette smoking, and disease, 370, 419
  and drug effectiveness, 577, 581
  preventive products and programs, 122, 210–212, 323
Cilla, Donald D., Jr., 435, 762
  "Student APhA: Pharmacy's Goodwill Ambassadors," 765–766
Cimetidine, 13, 61, 137, 138, 246, 288, 408, 588, 610, 778–779
Circadian rhythms, 582, 587
Cisplatin chemotherapy, 403, 582
Clark, David, 401
Cleary, Patrick, 723
Clements, Mary Lou, 337
Clindamycin phosphate, 507
Clinical notes *column*, 778–779
Clinical pharmacy, 40, 808–809
  and cost containment, 259–262
Clinical toxicology, 92–96
Clonazepam, 194, 200
Clonidine, 374, 376, 614, 650, 806
Clotrimazole, 140, 492, 660
Cloutier, Gilles, "Epilepsy: Patient Education and Services," 203–207
Cobb, R. David, 438
  "The Incontinent Patient: A Roundtable Discussion," 351–360
  "Pharmacy Computers: Regulation by Boards of Pharmacy," 220–223
Cochi, Steve, 180
Codeine, 296, 408, 740
Cohen, Stanley, 612
Cohon, Monte S., 70
Colaizzi, John L., 323
Colds medications, 246, 650, 659, 734–740
  cost and sales data, 409, 499
Colestipol, 585
Coleus plant extracts, 802
Community pharmacy, 326, 751, 808–809
  and capitation reimbursement, 263–264
  economic data, 169–172
  See also Marketing pharmacy services.
Community-based hypertension programs, 375, 377
Compassionate Pain Relief Act, 237, 715
Compliance. *See* Patient compliance.
Compounding, extemporaneous, 550–555
Computer systems, for ADR reports, 795–796
  for drug delivery, 69, 618
  for drug research, 69, 610
  for home health care, 645
  for medical information, 42, 682–688
Computer systems for pharmacy, 18–19, 40, 150–153, 261, 686–687, 689–694
  books, 98
  costs, 695–701
  state regulations on, 220–223
Consumer attitudes, toward health care, 253–254, 333–334, 640–641
  toward pharmacy services, 41, 111, 240, 336, 624–627, 644, 675
  toward prescription drug advertising, 10, 72–75, 240
Consumer information. *See* Patient information.
Contact lens-drug interactions, 48
Continuing education, 117–119, 750, 768
  listings, 50, 319, 557
Contraceptives, 140, 180, 408, 409, 422, 498, 584
Controlled substance look-alike drugs, 10
Controlled Substance Registrant Protection Act of 1984 [pharmacy crime law], 236, 331–332, 398, 729–732, 768
Controlled substances, 220–221, 328, 496, 710
  and pharmacy crime legislation, 331, 332
  See also Heroin.
Controlled Substances Act, 12, 220, 703
Controlled-release drug delivery systems, 615–618, 650, 740
Cooper, Theodore, 620, 793–794
Copayment plans, 328, 398, 400–401, 496
Cope, James D., 639
Corley, James H., 323
Coronary artery disease. *See* Cardiovascular disease.
Corticosteroids, 486
Cost containment, 62–63, 188–191, 258–264, 400, 425–428, 497–498, 543, 752–756
Cost-effectiveness of drug products, 497–498
Cote, Lynne, 147
Cough medications, 507, 734–740
  cost and sales data, 409, 499
Coulton, Claudia, 388, 389
Coury, John J., Jr., 19
Covert, John, 34, 86, 122, 240, 538, 744
Cowan, Kenneth, 176
Cowles, C. J., 435
Crackower, Sydney, "Pharmacists Were Sabotaging My Patient Care," 570–572
Crawford, D. Stephen, 329
Crawford, Roberta, 116, 623, 776
Cremer, Kenneth, 595
Cromolyn sodium, 140
Cutaneous candidiasis, 126
Cutaneous drug reactions, 795–796
Cyclamates, 655
Cyclophosphamide, 486, 584
Cyclosporine, 129–130
Cyclothiazide, 374

D

D'Achille, Kathleen M., 568
Dalton, David L., 6
Dangerous Drug Diversion Control Act, 496, 710
Dao, Thi, 497, 498
Data management systems. *See* Computer systems.
Davidson, Julian M., 722
Davis, Harold, 212
Davis, Robert E., 833
Deafness, 48
Deanfield, John, 581
Decongestants, 246, 736–738
Dee, Donald A., 6, 496
Degrees in pharmacy, 46, 96, 103–104, 742–751, 763
  See also Pharmacy education and training.
Deiner, Carl, 170, 172
Demeclocycline, 364
Dental care products, 182, 335–336, 585
Dental patients, drug therapy for, 806
The Dentist and the Pharmacist, 182
Depression, emotional, 511–514
Deremiah, Gloria K., 60
Derendorf, Hartmut, 250, 761
Dermatologicals, cost data, 409
Deshmukh, D. R., 141
De Vink, Lodewijk, 110, 111
DeVivo, D. C., 144
Dexamethasone, 298
Dexatrim, 10
Dextroamphetamine, 296
Dextromethorphan, 507, 740
Diabetes, 249–250, 336, 403, 409, 415–416, 678, 801, 824–837
Diabetes and the Pharmacist, 833
Diabetic hyperglycemia, 416, 510
Diabetic retinopathy, 647
Diagnosis Related Groups (DRGs), 43, 62, 63, 106, 258–264
Diazepam, 194, 200, 246, 408, 588, 788–789
  user profile, 115
Dice, J. R., 61
Diet, calcium-restricted, 139–140
  and drug activity, 577–578
Diet products, 10, 180, 416, 720
Dietary cholesterol, 114–115, 370, 373, 585, 654
Digestive products, sales data, 499
Digoxin, 408
Dilaudid, 239. *See also* Hydromorphone.
Dilger, Joseph, 435
Diltiazem, 374, 377
Diocytl sodium sulfosuccinate, 296
Diphenhydramine, 738, 740
Diuretics, 132–134, 373–376, 800
  cost data, 409
Douglas, John, 591
Dove, Susan, 709
Doxepin, 726
Doxycyline hyclate, 140

Doxylamine, 738
Drayer, Jan, 650
Driscoll, David F., "Theophylline Pharmacotherapy," 285–293
Driver behavior, and psychoactive drugs, 726
Drug abuse, 98, 227, 679, 765–766, 768
  See also Controlled substances; Prescription drugs, abuse of.
Drug allergy, 67–68, 167
Drug compounding, extemporaneous, 550–555
Drug-contact lens interaction, 48
Drug cost data, 409, 497–498
Drug delivery systems, 246, 338, 508, 608–620, 650, 740
Drug diversion, 328, 496, 710
Drug Efficacy Study Implementation (DESI), 501, 735, 797
Drug emergencies: drug manufacturers' telephone numbers, 378–386, 569
  Medic Alert, 348–349
  poison centers, 95
Drug Enforcement Administration, 220–223, 328, 331, 332, 494, 703, 710
Drug formularies, 260
Drug information for patients. *See* Patient information.
Drug information for pharmacists, 9, 88, 227
Drug interactions, 70, 288, 364, 369, 371, 473, 558–559, 739, 740
Drug labeling, 8, 9, 334, 402–403, 405, 500, 577–578, 646, 714
  See also Warning labels.
Drug Listing Act of 1972, 576
Drug names, *book*, 50
Drug news *column*, 122, 246, 338, 403, 507, 659, 728, 806
Drug packaging, 61, 207
Drug product selection, 64, 260
Drug profiles, for epileptics, 205–207
Drug reclassification, 12, 237, 619–620, 715
  See also Prescription-nonprescription (Rx-OTC) switch.
Drug terminology, 64
Drug utilization review (DUR), 4–5, 262
Drug Wholesalers Association, 236, 331
Dudrick, Stanley, 599, 601
Dujovne, Carlos, 585
Dunning Award, 437–438
Duodenal ulcer, 137–138, 778–779
Durham, Carl T., 185
Durham-Humphrey Amendments, 184, 185, 500, 709, 790–792
Dydek, George J., 323

E

Easton, James O., 729
Ebert Prize, 438
Econazole nitrate, 126, 128
Edloe, Leonard L., 6, 109, 407
Education. *See* Continuing education; Pharmacy education and training.
Edwards, William J., 109, 433, 445
  "1983 Financial Report: Unanticipated Success," 450
E-Ferol Aqueous Solution, and infant deaths, 405
Ehrlich, George, 174
Elderly patients, arthritis in, 473–486
  attitudes toward health care, 253, 644, 645, 675
  diuretics for, 373
  drug color coding for, 254
  drug effects on, 9, 126, 334, 410, 484, 577–578, 588
  drug use by, 408, 558, 766
  enteral nutrition for, 602
  health care services for, 756
  incontinence in, 351–360
  influenza immunization for, 503–504
  sleep disorders in, 13
Elechko, J. R., 492
Electroconvulsive therapy, 514
Electroencephalography, 194, 195, 250
Elliot, Edward C., 77
Ellis, Charles, 586
Ellis, William, 435, 762
  "Student APhA: Benefits and Opportunities," 764
Emala, Vivian Lee, 743
Emergency medical information, from Med-Card, 723
  from Medic Alert, 348–349
  from pharmaceutical manufacturers, 378–386, 569
Emergency scheduling of controlled substances, 328, 496, 710
Emotional disorders, 511–514
Employee pharmacists, 234–235, 396–397, 491, 632
Enalapril maleate, 374, 377
Endorphins, 611, 612
Engman, Lewis, 574, 639
Enkephalins, 612
Enteral nutrition products, 598–605
Enthoven, Alain, 586, 587
Enzyme-controlled drug release systems, 617–618
Enzyme deficiency diseases, 613
Ephedrine, 736, 737
Epidermolysis bullosa, 248
Epilepsy, 193–207, 397
Epilepsy Foundation of America, 205
Epinephrine hydrochloride, 48
Epinephryl borate, 48
Eraker, Stephen, 252, 253
Ergoloid mesylates, 140
Erythromycin, 288, 408, 506
Estrogens, 419, 422, 582, 584, 614, 646, 659, 718
Ethacrynic acid, 374, 376
Ethanol, 13
Ethical issues, 62, 82, 318, 554
Ethosuximide, 200
Etodolac, 761
Etomidate, 135
Etoposide, 131
Evaluations of Drug Interactions (EDI), 70
Evanson, Robert V., 407
Evens, Barbara, "Taking the Sizzle Out of the Sun," 362–366
Everett, Thomas, 722
Exercise, 381, 415, 422
Expectorants, 735, 739–740
Extemporaneous compounding, 550–555
Eye drops, 48, 409

F

Family pharmacy practice, 76–84
Family planning products. *See* Birth control products.
Farinas, E. R., 491
Fassett, William E., "Extemporaneous Compounding: Promotional and Legal Aspects," 550–555
Faust, Richard E., "Opportunities in Industry for Graduate-Degreed Pharmacists," 302–306
Fazio, Stephen J., 709
Fedder, Donald O., "Expanding Pharmacy Roles: An Issue of Priorities," 324–326
Federal Trade Commission, 712, 790–792
Fee-for-service reimbursement, 80, 83, 426
Feet, fatigue in, 658
Feinberg, Madeline, 491
Feldmann, Edward G., 402, 403, 573
Feminine hygiene products, 499
Fenoprofen, 479, 481
Ferguson, Lewis M., 167
Ferguson, Stacey A., 762
Figa, Fred, 405, 446
Fink, Joseph L., III, 451
  "Extemporaneous Compounding: Promotional and Legal Aspects," 550–555
  "Identifying the Pharmacist's Professional Status," 624–627
  "The Pharmacist's Responsibility to Determine Limits to Prescribing Authority," 702–703
  "Pharmacy Computers: Regulation by Boards of Pharmacy," 220–223
First aid information, 678
First-pass effect, 577
Fischelis, Robert P., 78
Fish, Catherine A., 397
Fleming, H. Harris, 438
Florio, James J., 712
Flowers, Franklin P., "Taking the Sizzle Out of the Sun," 362–366
Floyd, Gloria, 660
Flu. *See* Influenza.
Flunisolide, 728
Fluphenazine, 802
Flurazepam, 12, 587
Foege, William, 610, 614, 620
Foley, Kathleen, 238
Folic acid, 344
Folk medicines, 802
Follett, Mary Parker, 43
Food and Drug Administration (FDA):
  ADR reporting system, 793–794, 795–796
  on advertising prescription drugs, 10, 72–75, 240, 328
  on amrinone, 728
  on analgesics, 759
  on buspirone, 115
  on ceftizoxime, 338
  on cimetidine, 246
  on cold and cough medications, 735
  on combination analgesics, 245
  commissioner named, 402
  on controlled-release allergy drugs, 246
  on cyclamates, 655
  on diet aids, 10, 180, 416, 720
  on *E-Ferol*, 405
  on estrogens, 646
  on extemporaneous compounding, 551–555
  on flunisolide, 728
  on fraudulent health care products, 710
  on geriatric drug labeling, 9, 334, 577–578
  on hydromorphone, 122
  on injectable cephalosporin, 403
  on labeling for inactive ingredients, 402
  on methaqualone, 12
  on metoprolol, 338
  on minocycline, 122
  NDA process, 328, 342, 398, 405, 502, 553, 573, 574, 576, 580, 636, 720
  new drugs approved (1983), 123–140
  on nicotine chewing gum, 122, 210
  nonprescription drug review, 8–9, 184–187, 500–502
  on nonprescription ibuprofen, 404
  on nuclear pharmacies, 713
  on oral hypoglycemics, 415–416
  on oral theophylline, 286, 287, 797
  on orphan drugs, 248, 801
  on patient information, 575
  on pentoxifylline, 728
  on pharmaceutical industry, 304
  on phenylbutazone, 174–175, 714
  on poisonous herbs, 120–121
  on Reye-aspirin link, 142–143, 145, 789
  on sodium cellulose phosphate, 510
  on sulfonamides, 506
  on sunscreen products, 363
  on tampon labeling, 576
  on toxic shock syndrome, 180
  on transdermal nitroglycerin, 338
  on unapproved drugs, 576
  on urokinase, 122
  on U.S. drug use (1971–1982), 408–410
Food and Drug Law Institute, 500
Food, Drug and Cosmetic Act of 1938, 174, 287, 500–502, 552, 553, 555, 576, 702
  Drug Amendments of 1962, 501
  Durham-Humphrey Amendments of 1951, 184, 185, 500, 709, 790–792
Food-drug interactions, 569, 797
Food Marketing Institute, 236, 331
Foote, Robin A., 60
For-profit hospitals, 38, 41, 425, 753, 756
Formularies, 260
Forskolin, 802
Foster, Thomas S., 70
Fox, David, 339
Francke, Donald E., 78
Francke, Gloria N., 109
Fraudulent health care products, 710
Freedman, Michael L., "The Incontinent Patient: A Roundtable Discussion," 351–360
Frei, Emil, 14
Freud, Karl, 632
Friedman, Bernard, 63
Fungal infections, 126, 128
Furosemide, 364, 374, 376, 408

G

Gallopamil, 659
Gallstones, 138–139
Gamma-vinyl GABA, 194, 196
Gardner, Vincent, 639
Gardocki, Joseph, 13
Garrelts, Linda, 407, 674–681, 835
Gastric antisecretory agents, 137–138
Gelbach, Stephen, 119
Generic drug prescribing. *See* Nonproprietary

drug prescribing.
Generic substitution, *definition*, 64
Genetic disorders, 116, 248, 612–613, 622–623
Genetic engineering technology, 248, 336, 506–507, 611–615
Genital herpes, 412, 591–595
Genitourinary tract infections, 128–129
Gentamicin, 125
George, Homer A., 111
Gerbino, Philip P., 168
Geriatric drug labeling, 9, 334, 577–578
Geriatric patients. *See* Elderly patients.
Gerich, John, 510
Gibson, Patricia Ann, "Epilepsy: Patient Education and Services," 203–207
Gingivitis, 335–336, 585
Glipizide, 824–837
Glucose monitoring, 249–250, 510, 824–837
Glyburide, 403
Glycosylation, 824–837
Godzeski, Carol W., 475
Gold, for arthritis, 485–486, 584
Goldstein, Joseph, 569
Gonorrhea, 122, 652
Good Laboratory Practice (GLP) regulations, 303
Goodman, Dorothy P., "The Incontinent Patient: A Roundtable Discussion," 351–360
Gore, Albert, Jr., 573
Gout, 474–477
Grabenstein, John D., 167
Grabowski, Henry G., 580
Graduate Medical Education National Advisory Committee, 42
Gramm, Wendy, 712
Grammer, L. C., 336
Grant, Alexander, 10
Green, Charles R., 6, 109, 256
Greenblatt, David, 588
Griffenhagen, George B., 109, 111, 437
Guaifenesin, 739, 740
Guanabenz acetate, 374, 376
Guanadrel sulfate, 131–132, 374, 376
Guanethidine, 131, 132, 374–376
Gum disease, 335–336, 585
Gurwich, Ernest, "Treating Arthritis With Nonsteroidals," 478–481
Gysi, Charles L., 396

H

Haddad, William F., 574
Hague, Betsy, 237
Halder, Pieter, 601
Haloperidol, 719
Halperin, Jerome A., 103
Handbook of Nonprescription Drugs, 738, 758, 760
Harris, Mark, 581
Hatch, Orrin, 398, 405, 574, 710
Havender, William, 655
Haverkost, Lawrence F., 790–792
Hay fever, 679
Hayes, Arthur Hull, 56, 72, 402
Health and Human Services Department (HHS), 116, 142–143, 174, 175, 211, 237, 446
Health care, consumer attitudes toward, 253–254, 333–334
  fraud in, 710
  preventive, *book*, 558
Health care costs. *See* Cost containment.
Health Check Test (HCT), 187, 680
Health insurance, effects on health status, 182
Health Maintenance Organizations (HMOs), 41, 63, 107, 171, 188–191, 263, 425–428, 753, 754
  cost-effectiveness of, 586–587
Health Manpower Act of 1972, 755
Health Professions Education Project (HPEP), 181
Health Research Group (HRG), 174, 402, 714
Hearing disorders, 48
Heart disease 114–115, 122, 140, 370, 373, 614, 728
  See also Angina.
Heckler, Margaret, 8, 175, 258, 446, 637, 714, 719
Heller, William M., 436, 639
Helms, Robert, 638
Hemochromatosis, 116, 622–623
Hemophilia, 612
Hendeles, Leslie, 633
Henrich, William, 339
Hepatitis B, 506–507, 679
Hepatotoxicity, 479, 759, 760
Herbs, poisonous, 120–121
Hereditary disorders, 116, 248, 612–613, 622–623
Heroin, reclassification of, 237–239, 715
Herpes simplex, 412, 591–595, 614
Herpes zoster, 140
Herzberg, F., 216
Hexachlorophene, 8
High blood pressure. *See* Hypertension.
High-pressure liquid chromatography, 252
Hill, Martha N., "Collaboration in High Blood Pressure Control," 810–812
Hindmarsh, Ian, 726
Holistic health care, 388–390, 780–783
Home health care, 39, 42, 148–149, 187, 600, 645, 768, 808–809, 824–837
Home health care centers, 42, 236, 496
Home test kit for stool blood, 654–655, 659–660
Homeopathy, 780–783
Hormone prescriptions, cost data, 409
Hormones, neurotropic, 611
Hospices, pain management in, 294–299
  pharmacist's role in, 146–149, 388–390
Hospital computer systems, 684–685
Hospital corporations, 38, 41, 425, 753, 756
Hospital pharmacy, 258–264, 808–809
  and pharmacokinetic dosing services, 778
Hoth, Dan, 342, 350
Houde, Raymond, 237, 238
Hrushesky, William, 582
Hsiao, William, 63
Hughes, William J., 236, 328, 331, 332, 710, 729, 731, 732
Hulka, Barbara, 582
Human insulin, 824–837
Humphrey, Hubert H., 79, 185
Humphrey Award, 436
Humphries, T. J., 61
Hurd, Peter, 254
Hussar, Daniel A., 556, 793–794
  "New Drugs of 1983," 123–140
Hutt, Peter Barton, 500–502, 793–794
Hyde, Henry J., 331, 332
Hydralazine, 374, 375, 377
Hydrochlorothiazide, 364, 374, 408
Hydrocortisone, 8
Hydroflumethiazide, 374
Hydromorphone, 122, 239, 296
Hydroxychloroquine, 483
Hydroxyzine, 296
Hypercalciuria, 139–140, 510
Hypercholesterolemia, 114, 585
Hyperglycemia, 249, 416, 510, 824–837
Hypertension, 119, 131–134, 368–377, 422, 588, 614, 650, 800, 810–812
  screening by pharmacists, 674–676, 681
Hypertension Detection and Follow-up Program (HDFP), 371, 372
Hypertrichosis, 375
Hyperuricemia, 373
Hypnosis, in pain management, 299
Hypnotics, 11–13, 134–135, 726
Hypocitraturia, 510
Hypokalemia, 373

I

Iatrogenic illness, 252
Ibuprofen, 350, 408, 479, 481, 584
  nonprescription, 104, 404, 758–761
Illicit drugs. *See* Controlled substances.
Imipramine, 364, 511
Immune deficiencies, 507, 611–613
Immunization, for influenza, 503–504
Immunomodulators, 611
Immunosuppressives, 129–130
Implantable drug delivery systems, 42, 43, 508, 616, 824–837
Incontinence, 351–360
Indapamide, 132–133, 374
Individualized drug regimens, for cancer, 14–15, 69
  for diabetes, 415–416
  for pain management, 294–299
  and patient compliance, 252–253
Indole analogs, 480
Indomethacin, 410, 480, 481, 788–789
Industrial Pharmacy Award, 439
Infant formula, 728
Infectious diseases, 614, 734–740
Influenza, 142, 337–338, 614–615, 679
  immunization guidelines, 503–504
Information management systems. *See* Computer systems.
Injectable drugs, *book*, 99
Inotropic drugs, 728
Insomnia, 11–13, 134–135, 587
Insulin, 336, 510, 824–837
Interferon, 611
Intracerebral injection drug delivery systems, 617
Intranasal drug delivery systems, 617, 737
Ipecac, 94, 677, 740
Iron Overload Diseases Association, 116, 623
Islet cell transplantation, 801
Isotretinoin, 507, 586

J

Jaffe, Israeli, 175
Jensen, C. Neil, 401
Jet-lag effects, 587
Jick, Hershel, 339
Jock itch, 126
Johnson, Robert C., 324
  "Reaching Out For New Professional Opportunities," 105–108
Johnson and Johnson home health care centers, 42, 236, 496
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, 368, 371, 675, 800
Jollow, David, 652
Jolly, Charles N., 790–792
Jones, Judith, 793–794

K

Kaiser, Leland, 44
Kalman, Samuel H., 744
  "Managing Change: Marketing and Pharmacy," 41–43
Kalsman, Kathy, 147
Kanamycin, 125
Kaufman, David, 582
Kaye, Ronald L., "A Clinical Perspective on Rheumatoid Arthritis, Osteoarthritis, and Gout," 474–477
Kellen, Robert, 655
Kendall, Alan, 620
Kenna, F. Regis, 236
Kennedy, Tom, 804
Keville, Dorothy A., 710
Kidney dysfunction, 243–245, 479, 484, 760
  and NSAIDs, 339, 350, 480, 481
Kidney stones, 139–140, 422, 510
Kidney transplant rejection, 129–130
Kilmer, Fred, 80
Kilwein, John, 115
Kinnard, W. J., 92
Kirk, Kenneth W., 60, 215, 217, 349, 660
Kirking, Duane M., 777
Kirscht, John, 252
Klayman, Harry, 397
Kline Company report on nonprescription drug sales, 499
Knapp, David A., 438
  "Placebos: Who's Being Fooled?" 4–5
Knapp, Dee A., "Placebos: Who's Being Fooled?" 4–5
Koda-Kimble, Mary Anne, 743
Konnor, Charma A., 6
Koop, C. Everett, 145
Korberly, Barbara, 104
Krause, Richard M., 67
Krigstein, David J., 743
Kristol, Irving, 435
Kuhn, Ralph S., 77
Kupfer, David, 511
Kurlander, Bernard J., 103
Kurtz, T. W., 119
Kutsop, Joseph Jeffrey, 104, 778–779

L

Labeling, for geriatric patients, 9, 334, 577–578
  See also Drug labeling.
Labetalol, 374, 376, 728
Lachman, Branton G., "Can I Afford a Computer?" 695–701
  "Will Your User-Friendly System Bite Your Hand After Six Months?" 689-694
Lactation, drug effects on, 61, 323, 415–416, 483, 486
Lactose intolerance, 600–601
Lacy, Katherine, 181

Landauer, Ali, 726
Langer, Robert, 617
LaPorte, Bruce P., 776
Larson, Rocky L., "Effective Communication In Emergency Situations: Pharmaceutical Companies' Telephone Numbers," 378–386
Laska, E. M., 414
Launer, Michael, 602
Lauper, R. David, 60
Lavender, Albert, 713
Leadership training, 660
Lecithin, 180, 617
Lee, Michael B., 182
Legionnaires' disease, 679
Legs, fatigue in, 658
Lehrman, Sandra, 594, 595
LeMaistre, Charles A., 743, 750
Lemberger, August P., 306, 438
Lemberger, John R., 708
Lemmon Company, halts methaqualone, 12
Lent, Norman F., 712
Leonard, Rodney, 655
Leone, Daniel C., 401
Lesch-Nyhan syndrome, 613
Leucovorin calcium, 140
Leukotrienes, 614
Levodopa, 299
Levorphanol, 296
Levothyroxine, 252
Liability insurance for pharmacists, 233
Liberman, P., 203
Licensing. *See* Professional licensure and certification.
Lichtenstein, P. K., 144
Lien, Eric J., 61
Lilly Digest economic report, 169–172, 406–407
Lipid Research Clinics, 114
Liposomes, 617
Lippman, Frederic, 436
Lipscomb, Jack, 344, 350
Liquid antacids, 778–779
Liquid controlled-release drug delivery systems, 616
Lissack, Stanley A., 433
Lithium, 133, 288, 511–514
Litovitz, Toby, "The Pharmacist's Role in Toxicology," 92–96
Liver toxicity, 479, 759, 760
Localized drug delivery systems, 616, 617
Long-term care facilities, pharmacist's role in, 108
Look-alike drugs, 10
Loperamide, 806
Lorazepam, 778–789
Luken, Thomas A., 331, 332
Luther, Ernest H., 777
Lutz, Lawrence, "Computers and Health Care," 682–688

M

Maddox, Ray R., "Epilepsy: Current Therapeutics," 197–202
Magnetic drug delivery systems, 616
Main, James A., 109
Malnutrition, in hospitals, 601–602
Management. *See* Pharmacy management.
Mangione, Robert A., 168
Manhardt, P. J., 216
Manic-depressives, 511–514
Margolis, Marya B., 491
Marketing health care services, 752–756
Marketing pharmacy services, 41–43, 187, 262, 605, 636, 679–681, 805, 835
Marshall, Robert P., 328
Martineau, Frank, 122
Marttila, James K., 70
Maryland Poison Center, 92–96
Max, Mitchell, 298
Maximum Allowable Cost (MAC) program, 446
Maxmen, J. S., 44, 45
Maze escape drug delivery systems, 615
McCarron, David, 588, 800
McConnell, Warren, 44
McDaniel, Anthony, "The Pharmacist's Responsibility to Determine Limits to Prescribing Authority," 702–703
McDonald, Donald E., 236
McGinty, Laurel, 475
McGregor, Thomas, 182
"Can Independent Pharmacy Survive?" 169–172
McKean, Suzanne, 612
McKee, Shirley P., 451
McKesson Drug, and pharmaceutical centers, 84
Meclofenamate, 481
Med-Card system, 723
Medic Alert system, 348–349
Medicaid, 4, 189, 191
and copayment, 328, 398, 400–401, 496
Medical [California] computer system, 692–693
Medical Information Network (MINET), 42
Medical Information systems, computerized, 42, 682–688
Medicare, DRG reimbursement system, 43, 62, 63, 106, 258–264
Mefenamic acid, 410
Megadose vitamins, 343–344, 350, 633
Meningitis, 338
Mercaptopurine, 486, 584
Merrill, Richard, 15
Mestranol, 419, 718
Methadone, 186, 296
Methaqualone, 12
Methotrexate, 176–177, 584
Methotrimeprazine, 298
Methyclothiazide, 374
Methyldopa, 131, 374, 376, 408
Metoclopramide, 140, 403
Metocurine, 136
Metolazone, 374
Metoprolol tartrate, 338, 373, 374, 376
Meyer, Harry, Jr., 287, 501
Mezlocillin, 410
Michels, Daniel L., 720
Michigan Pharmacists Association, 190, 836
Michigan State Pharmaceutical Association, 562–564
Michocki, Robert J., "Placebos: Who's Being Fooled?" 4–5
Microencapsulation research, 69
Microwave ovens, danger to transdermal patches, 412
Miller, Marion, 652
Miller, Roger, 143
Miller, Steven J., 776–777
Millis report on pharmacy education, 44
Millstein, Lloyd, 334
Minocycline, 122
Minoxidil, 374, 375, 377
Mirsky, Howard A., 323
Misher, Allen, 556
Mitchell, Edgar W., 585
Molecular drug delivery systems, 615
Monoamine oxidase inhibitors, 514
Monoclonal antibodies, 15, 69, 610, 613–614, 617
Mood disorders, 511–514
Moore, R. C., Jr., 119
Morgan, Robert, 655
Morphine, 237–239, 296, 508–509
Morris, Louis, 75
Morse, Franklin I., 104
Moss, Charles, 658
Motion sickness, 614
Mountain, Richard, 410
Mouthwashes, 335–336, 585
Moxalactam, 125, 410
Mrtek, Robert G., 233
"Office-Based Pharmacy in the United States: The Development of a Practice Alternative," 76–84
Multiple Risk Factor Intervention Trial (MRFIT), 371
Murphy, Brian, 337
Murphy, Gerald, 388, 389
Myasthenia gravis, contraindicated drugs, 126, 136
Mycoplasmal throat infections, 66
Myers, Charles, 176, 178
Myerson, Ralph M., 61
Myocardial infarction, 122, 140, 614
See also Heart disease.

N

Nader, Ralph, 402
Nadolol, 373, 374, 376
Naisbitt, John, 19
Nalbuphine, 298
Nalidixic acid, 364
Naproxen, 479, 481
Nasal decongestants, 737
National Ambulatory Medical Care Survey (NAMCS), 4
National Association of Boards of Pharmacy Examination (NABPLEX), *review book* for, 227
National Association of Chain Drug Stores, 236, 331, 636, 729–732
National Association of Retail Druggists, 185, 732
National Cancer Institute, 69, 211, 212, 342
National Center for Health Services Research, 96
National Center for Health Statistics, 4
National Clearinghouse for Alcohol Information, 181
National Committee on the Treatment of Intractable Pain, 237
National Council on the Aging, 389
National Council on Patient Information and Education (NCPIE), 65–66, 546, 575–576
National Council of State Pharmaceutical Association Executives, 398, 400–401, 496, 632
National health observances, 111, 681
National Health Promotion Initiative for the Elderly, 645
National Heart, Blood, and Lung Institute, 114–115
National Heart, Blood, and Lung Advisory Council, 377
National High Blood Pressure Education Program, 368, 810–812
National Institute on Alcohol Abuse and Alcoholism, 181
National Institute for Allergy and Infectious Diseases, 591–595
National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, 802
National Institute of Child Health and Human Development, 584
National Institutes of Health, 11–13, 194, 243, 250, 417, 511–514, 646, 718
National Medication Awareness Test (NMAT), 65, 187, 674, 679–680
National Pharmaceutical Council, 764
National Poison Prevention Week, 111
National Wholesale Druggists' Association, 236–331
Nebraska Pharmacists Association, 328, 445
Neff, Thomas, 410
Nelson, Linda, 182
Neoplastic disorders. *See* Cancer.
Nephrotoxicity, 126, 130
Netilmicin sulfate, 125–126
Neuroleptic drugs, 802
Neurotransmitters, 611, 617
Neurotropic hormones, 611
New dosage forms, 122, 140, 246, 338, 403, 507, 806
New drug delivery systems, 246, 338, 508, 608–620, 650, 740
New drugs, research on, 14–15, 69, 176–178, 196, 248, 337–338, 342, 350, 412, 506–510, 582–584, 608–620, 647, 719, 723
New drugs approved (1983), 123–140
New drugs approved (1984), 122, 246, 338, 403, 404, 728, 806
New Hampshire Pharmaceutical Association, 710
New indications for approved drugs, 122, 140, 338, 659
Newcomb, Jack, 443
Niacin, toxic effects, 344
Nice, Frank J., "Women In Pharmacy Management: Why Not?" 214–219
Nicotine chewing gum, 122, 210–212, 323
Nifedipine, 374, 377, 410, 581
Nightingale, Stuart L., 145, 569
Nitrazepam, 200
Nitroglycerin, 185
controlled-release, 797
transdermal, 338, 412, 569, 614
Nitrous oxide, 299
Noncompliance. *See* Patient compliance.
Nongonococcal urethritis, 122
Nonoxynol, 9, 140
Nonprescription analgesics, 758–761
Nonprescription cold and cough medications, 246, 409, 499, 507, 650, 659, 734–740
Nonprescription drug review, 8–9, 184–187, 500–502
Nonprescription drugs, cost and sales data, 333–334, 408–410, 499
labeling of, 402–403
Nonprescription ibuprofen, 104, 404, 758–761
Nonproprietary drug prescribing, 119, 788–789
Nonsteroidal anti-inflammatory drugs (NSAIDs), 174–175, 248, 295, 339, 350, 410, 478–481,

584, 761, 795–796
Norfloxacin, 652
Norris, Ronald V., 552
Novitch, Mark, 8, 9, 73, 75, 402, 405, 576, 638, 788–789
Nuclear pharmacies, 713
Nuclear Regulatory Commission, 713
Nursing homes. *See* Long-term care facilities.
Nutritional supplements, cost and sales data, 409, 499
  enteral, 598–605
  for neonates, 806
Nutritional support services in hospitals, 262
Nuzzio, Linda, 147

O

Ocampo, Joseph O., "Can I Afford a Computer?" 695–701
Oddis, Joseph A., 639
Oderda, Gary M., "The Pharmacist's Role in Toxicology," 92–96
Office-based pharmacy, 76–84, 167, 233
Office of Science and Technology Policy, 798–800
Oftebro, John, 148
Oksas, Richard, 803
Oldstone, Michael, 610
O'Malley, Tom, 731
Oncogenes, 15, 613
Oncology. *See* Cancer.
Ophthalmic preparations, 48, 409
Opiate tolerance, 508–509
Oppenheimer, Phillip R., "Can I Afford a Computer?" 695–701
  "Will Your User-Friendly System Bite Your Hand After Six Months?" 689–694
Oral acyclovir, 412, 591–595
Oral antidiabetics, 403, 415–416
Oral candidiasis, 140, 492
Oral contraceptives, 408, 422, 584
Oral decongestants, 737–738
Oral hygiene products, 335–336, 585
Oral hypoglycemics, 403, 415–416
Oral theophylline therapy, 285–293, 410
Organ transplant rejection, 129–130
Orphan drugs, 116, 248, 510, 622–623, 719, 801
Orphan Products Board, 116
Osmotic drug delivery systems, 615–616, 720
Osteoarthritis, 474–477, 761
Osteoporosis, 417–423, 646, 718
Ottinger, Richard L., 403
Outpatient pharmacy, 38–40
Over-the-counter (OTC) drugs. *See* Nonprescription drugs.
Oxazepam, 788–789
Oxicams, 481
Oxprenolol, 374, 376
Oxymetazoline, 736, 737
Oxyphenbutazone, 174–175, 410, 714
Ozols, Robert, 176, 177

P

Pain, intractable, 122, 237–239, 294–299, 508–509, 715
Pak, Charles, 510
Pancuronium, 136
Para-aminobenzoic acid (PABA), 363–364
Paramethadione, 200
Parashos, Peter, 147
Parenteral drugs, *book*, 99
Parker, Howard E., 61
Parker, Luther, 400, 401, 632
Parkinsonism, contraindicated drugs, 126
Parks, Lloyd M., 743, 747
Patent term legislation, 328, 398, 502, 574, 788–789
Patient care, 778–779
Patient compliance, 115, 194, 205, 252–253, 546–548, 568–569, 650, 766
Patient counseling facilities, 39
Patient information on: alcohol abuse, 181
  arthritis, 482, 485, 486
  compliance, 252–253
  dental products, 182
  diabetes, 678, 824–837
  diet and cancer, 15
  drug abuse, 679
  epilepsy, 203–207
  first aid, 678
  hay fever, 679
  hepatitis, 679
  hypertension, 368–377, 675
  incontinence, 351–360
  influenza, 504, 679
  isotretinoin, 507
  legionnaires' disease, 679
  osteoporosis, 718
  pediatrics, 676–678
  poison prevention, 111, 676, 677
  pregnancy, 678
  sickle cell anemia, 679
  smoking cessation, 211–212, 323
  stool blood, 654–655, 659–660
  theophylline, 292
  See also Home health care.
Patient information telephone service, 803
Patient package inserts, 253
Patient profiles, for epileptics, 205–207
Pediatrics, patient information on, 676–678
Penicillamine, 483–485, 584, 720
Penicillin, 67, 68, 408, 652
Penna, Richard, P., 65, 103, 110, 143
  "Preferred Provider Organizations: How Burning an Issue?" 188–191
Pentazocine, 298
Pentoxifylline, 728, 824–837
Peot, Craig B., 492
Pepper, Claude, 710
Perchak, George J., 168
Pergola, Charles A., 402
  "Making the Most of the Rx-OTC Switch: An Interview with Charles A. Pergola," 86–90
Peskoe, Michael, 75
Pharmaceutical Advertising Council, 710
Pharmaceutical alternates, *definition*, 64
Pharmaceutical centers, 76–84
Pharmaceutical industry, career opportunities in, 46, 302–306, 492
Pharmaceutical manufacturers, 86–90, 186
  emergency telephone numbers, 378–386, 569
Pharmaceutical Manufacturers Association (PMA), 236, 331, 497–498, 798–800
Pharmaceutical substitution, *definition*, 64
Pharmaceutical Survey (1946–1949), 77, 78
Pharmacist prescribing, 107–108, 168, 703
Pharmacist's role in: computerized information processing, 686–687
  detecting ADRs, 793–794
  determining prescribing authority, 702–703
  diabetes, 824–837
  enteral nutrition, 603–605
  epilepsy, 203–207
  hospices, 146–149, 388–390
  hypertension screening, 674–676, 681, 810–812
  long-term care facilities, 108
  marketing pharmacy services, 41–43, 187, 262, 605, 636, 679–681
  new drug delivery systems, 619
  patient education, 39, 110–111, 674–681, 734–740
  poison prevention, 92–96, 167–168, 677
  preventive health care, 558
  toxicology, 92–96
Pharmacist-dentist relations, 182
Pharmacist-physician relations, 19, 64, 107, 236, 546–548, 570–573, 641–642, 708–709
Pharmacists, Burroughs Wellcome awards to, 804–805
  career opportunities for, 46, 302–306, 492, 762, 763, 767–768
  consumer attitudes toward, 43, 111, 240, 624–627
  contributions to APhA, 16
  employee, 234–235, 396–397, 491, 632
  impaired, 496
  job satisfaction of, 214–219, 347, 349
  liability insurance for, 233
  People *column* on, 51, 99, 164, 316, 318, 350, 556, 771, 858
  professional image of, 624–627, 768
  salaries of, 349
  women, 214–219, 349, 397, 626–627, 660
Pharmacokinetics, 9, 69, 262, 303, 761
Pharmacy Arthritis Information Network (PAIN), 473
Pharmacy associations, 19, 328, 445, 538–544, 573, 770
  See also American Pharmaceutical Association.
Pharmacy crime, 236, 239, 331–332, 398, 636, 729–732, 768, 770
Pharmacy Crime Bill Action Guide, 729–732
Pharmacy design, 39, 76–84
Pharmacy economics, 169–172, 400–401, 406–410, 425–428, 568, 838–842
Pharmacy education and training, 44–47, 60, 65, 96, 103–104, 108, 117–119, 227, 636, 742–751, 762, 763, 767–768
Pharmacy law (England), *book*, 318
Pharmacy management, computer technology in, 18–19, 40, 98, 150–153, 220–223, 261, 686–687, 689–701
  leadership in, 60, 660
  professional image, 624–627, 768
  residency program in, 407, 443
  telephone technology in, 308–315
  trends in, 41–43
  women in, 214–219, 397
  See also Academy of Pharmaceutical Management.
Pharmacy ownership, 838–842
Pharmacy profession, future of, 18–19, 38–43, 105–108, 236, 324–326, 425–428, 538–544, 808–809
Pharmacy schools. *See* Pharmacy education and training.
Pharmacy students, 435, 762–770
  and patient education activities, 762–763, 765–766
Phenacetin, 243–245
Phenformin, 415
Phenindamine, 738
Pheniramine, 738
Phenobarbital, 194, 195, 198–199, 288, 408
Phenothiazines, 298, 334
Phenylanthranilic acids, 481
Phenylbutazone, 174–175, 410, 480–481, 714
Phenylephrine, 736
Phenylethylmalonic acid, 199
Phenylpropanolamine, 10, 246, 650, 720, 736
Phenylpropionic acids, 479–480
Phenytoin, 194, 198, 288
Photophobia, 483
Photosensitivity, 364–365
PHYCOM (Physician Communication) Service, 42
Physician dispensing, 42, 60, 456–457
Physicians, attitudes toward health care system, 640–641
  prescribing authority of, 702–703
Pickar, David, 802
Pill-pump drug delivery systems, 615–616
Pimozide, 719
Pindolol, 374, 376
Piperacillin, 410
Piroxicam, 481
Pityriasis versicolor, 126
Plaa, Gabriel, 793–794
Placebo therapy, 4–5
Plaque, arterial, 728
  dental, 335–336, 585
Poison control centers, *list*, 95
Poison prevention, 92–96, 111, 167–168, 676, 677, 765
Poison Prevention Week, 111
Poisonous herbs, 120–121
Pollard, Michael R., 498
Polythiazide, 374
Porter, Roger, 194
Positron emission tomography, 194–195
Potassium, 373, 374, 376, 408, 588
Potassium citrate, 510
Potassium guaicol sulfonate, 740
Powers Research Achievement Award, 439
Praziquantel, 128
Prazosin, 374, 376
Preferred Provider Organizations (PPOs), 43, 63, 107, 171, 188–191, 256, 323, 425, 427, 712
Pregnancy, and antiepileptic drugs, 196
  contraindicated drugs, 122, 129, 135, 139, 404, 415–416, 484, 486, 507
  and diabetes, 824–837
  and influenza immunization, 503–504
  and lecithin, 180
  patient information on, 678
Premarket approval process. *See* ANDAs/NDAs.
Prescribing authority, 702–703
Prescription drugs, abuse of, 493–495, 632
  advertising of, 10, 72–75, 240, 328, 562–564
  development costs of, 580–581
  retail cost and sales data, 169–172, 406–410, 578, 580–581, 644
Prescription-nonprescription (Rx-OTC) switch, 86–90, 184–187, 492, 499, 500–502, 573, 735,

737, 768, 790–792
See also Nonprescription ibuprofen.
Preventive health care, *book*, 558
Primidone, 199
Probucol, 585
Procainamide, 68, 659
Professional licensure and certification, for pharmacist prescribing, 108
for state continuing education requirements, 117–119
Professional meetings. *See* American Pharmaceutical Association Annual Meeting report; Calendar of professional meetings.
Progabide, 194, 196
Progestogens, 422
Proglumide, 508–509
Promethazine, 364, 408
Propoxyphene, 408
Propranolol, 140, 288, 373, 376, 408, 577, 581, 788–789
Proprietary Association, 86–90, 333–334, 402–403, 636
Proprietary drugs, patent protection for, 788–789
Propylhexedrine, 736
Prospective payment, 258–264
Prostacyclin, 614
Prostaglandins, 614, 726, 759
Pseudoallergy, 67
Pseudoephedrine, 647, 736
Psychoactive drugs, effects on driving, 726
Psychotherapeutic drugs, cost data, 409
Psychotherapy, 514
Public Citizen's Health Research Group, 174, 402, 714
Public Health Service (PHS), 143–144, 645
Public relations for pharmacy. *See* Marketing pharmacy services.
Pulse-released drug delivery systems, 616, 617
Pyrazolones, 480–481
Pyridoxine, 344
Pyrilamine, 738

Q

Quaalude, 12
Quinethazone, 374
Quinidine, 806

R

Rachanow, Gerald, 577
Radiopharmaceuticals, 323, 713
Ranitidine, 137–138, 610
Rauwolfia, 374, 376
Recombinant DNA technology. *See* Genetic engineering technology.
Regelson, William, 237
Regional poison control centers, *list*, 95
Reimbursement, capitation plans, 263–264, 426
copayment plans, 328, 398, 400–401, 496
Diagnosis Related Groups (DRGs), 43, 62, 63, 106, 258–264
fee-for-service plans, 80, 83, 426
for hospice services, 148
third-party payment plans, 169–172, 400–401, 425–428
See also Health Maintenance Organizations; Pharmacy economics; Preferred Provider Organizations.
Relicensure. *See* Professional licensure and certification.
Remington Medal, 436
Renal dysfunction. *See* Kidney dysfunction.
Research Achievement Award, 438–439
Reserpine, 374, 376
Respiratory drug delivery systems, 616–617
Respiratory tract infections, 48, 734–740
Retinopathy, 483, 647
Reye, R.D.K., 141
Reye syndrome, and aspirin, 141–145, 789
Rheumatoid arthritis, 473–486, 584, 720, 760–761
Rhinitis, 140
Rhode Island Pharmaceutical Association, 710
Rhudy, Marily H., 109, 448
Rice, Rose, 652
Rifampin, 48
Rifkind, Basil, 114
Ringworm, 126
Robb, G.L., 94
Robinson, Daniel, 69
Robinson, Paul H., 433
Roccella, Edward J., 492
Rogers, Paul G., 575
Rogers, Robert, 147, 149
Rongey, Charles, 212
Rooney, James, 593
Roter, Deborah, 66
Roueche, Berton, 609
Ruggieri, Nicholas, 189
Runge, Mary Munson, 316
Rupp, Michael T., 492
Rx-OTC switch, 86–90, 184–187, 492, 499, 500–502, 573, 735, 737, 768, 790–792

S

Safety drug containers, 61
Salicylamide, 250
Salicylates, 141–145, 478–479, 726
Salt intake, and hypertension, 119, 370, 373, 588, 800
Sammons, James H., 19, 710
Sawyer, Harold S., 332
Scarlett, Thomas, 720
Schaefer, Hugo H., 58
Schaefer Award, 437
Schering Corporation "Ask Your Pharmacist" campaign, 110–111
Schering Reports, on consumer attitudes, 111
on pharmacist-physician relations, 641–642
Schiff, Gordon, 793–794
Schistosomiasis, 128
Schizophrenia, 802
Schlegel, John F., 329, 330, 398, 431–433, 440, 444, 446, 496, 562, 568, 573, 575, 636–639, 710, 730, 732, 765
"Extending Clinical Pharmacy Practice," 808–809
"New Ideas for Pharmacy's 'Foundation Organization': An Interview with American Pharmaceutical Association President John F. Schlegel," 538–544
Schondelmeyer, Stephen W., 445, 790–792
"Women In Pharmacy Management: Why Not?" 214–219
Schrier, Robert, 339
Schweiker, Richard, 142, 143
Schwirian, P.M., 218
Scolnick, Edward, 506, 507
Scopolamine, 614
Seidel, Wesley, 587
Seidlin, Mindell, 594
Seife, Marvin, 797
Seizures, epileptic, 197–202
Self care. *See* Home health care.
Self Medication Awareness Test (SMAT), 65, 187, 680
Senna concentrate, 296
Serum drug assays, 778
Serum hepatitis. *See* Hepatitis B.
Sesin, G. Paul, 778
Sesti, Louis M., 190, 401
Sexually-transmitted diseases, 122, 412, 507, 591–595, 611, 652
Shaw, Jane, 615, 617
Sheffield, Jean, 349
Shelby, Richard C., 638
Shepard, M.D., 215, 217
Shilling, Joseph, 149
Shingles, 140
Shinn, Arthur F., 70
Shoup, Larry K., 743
Shubin, Alan, "The Incontinent Patient: A Roundtable Discussion," 351–360
Sickle cell anemia, 679
Siecker, Bruce R., "New Technology in a Pharmacy," 150–153
"Taking Advantage of 'Super-Phone' Technology," 308–315
Silvestri, Carmela M., 435
"Student APhA: Changing Attitudes Toward a Changing Profession," 762–764
Simon, Lee, 475
Simos, Daniel M., 729
Simpson, Robert W., 475
Sing, Charles, 116
Sinus medications, 499
Siperstein, Marvin, 249, 250
Skahl, John T., 401
Skeletal abnormalities, 586
Skeletal muscle relaxants, 136–137
Skin disorders, 586
Skin types, sensitivity of, 362–366
Sleep disorders, 11–13, 134–135, 587
Smith, Carol A., 475
Smith, Debra A., 660
Smith, Dorothy L., 65
Smith, George Teeling, 302, 608, 618
Smith, Lawrence J., 332
Smith, Mickey C., 323
Smith Award, 437
Smith Kline and French Laboratories arthritis information network, 473
Smits, Helen, 62
Smoking. *See* Cigarette smoking.
Smoking-cessation products and programs, 122, 210–212, 323
Sodium, in antacids, 712
and hypertension, 119, 370, 373, 588, 800
Sodium cellulose phosphate, 139–140, 510
Sodium fluoride, 718
Sodium salicylate, 726
Software, for medical information, 645, 682–688
Somin, Arnold, 581
Sorbinal, 647
Spectinomycin, 652
Spironolactone, 374, 376
Staite, Nigel, 720
Standards of Practice, 742–744, 750
State boards of pharmacy, computer use regulations, 220–223
continuing education requirements, 117–119
NABPLEX *review book*, 227
State-national pharmacy association relations, 19, 328, 710
State pharmaceutical associations, 65, 186
See also by name of state.
Steroids, 8, 298, 363
Stetler, C. Joseph, 109
Steward, Joseph, 580
Stoffer, Sheldon, 252
Stollman, Max, 437
Straus, Stephen E., 591–593
Strep infections, throat cultures for, 66
vaccines for, 723
Student American Pharmaceutical Association, 435, 762–770
Substance abuse, *book*, 227
See also Alcohol abuse; Drug abuse; Prescription drugs, abuse of.
Substitution laws. *See* Drug product selection.
Succinylcholine, 136
Sugar substitutes. *See* Artificial sweeteners.
Sulfamethoxazole, 364, 408, 506
Sulfisoxazole-erythromycin combination, 506
Sulfonamides, 374, 376, 506
Sulfonylureas, 415–416
Sulindac, 339, 350, 480, 481
Sunburn, 362–363
Sunscreen products, 362–366
Sustained-release medications, 246, 615–618
Sutton, Steven C., 569
Sweet spirits of nitre, 8
Sweeteners, artificial. *See* Artificial sweeteners.
Synder, William, 712
Syrup of ipecac, 94, 677, 740
Szeinbach, Sheryl L., "Identifying the Pharmacist's Professional Status," 624–627
Szpunar, Walter, 252

T

Taffet, Richard M., 569
Talley, James Robert, "Medicare's Prospective Payment System," 258–264
Tamoxifen citrate, 338
Tamper-resistant packaging, 61
Tampons, and toxic shock syndrome, 180, 576
Tang-Liu, Diane, 397
Tanner, Sidney, 396
Tanning. *See* Sunburn.
Task Force on Pharmacy Education, 636, 742–751
Task Force on Women in Pharmacy, 660
Taurine, 728, 806
Tax Equity and Fiscal Responsibility Act (TEFRA), 328
Taylor, Jennifer S., 435, 762
"Student APhA: Putting Policy into Action," 767–770
TeGroen, D.M., 658
Telephone technology, 308–315
Temazepam, 12
Temple, Robert, 404, 577

Temples, Thomas E., 509
Tennyson, Danny D., 709
Terminally ill patients. *See* Hospices.
Terpin hydrate, 740
Tetracycline, 364, 408, 652
Texas Pharmaceutical Association study on job stress, 347, 349
Thakker, Kamlesh, 69
Theeuwes, Felix, 439
Theophyllines, 285–293, 408, 509, 576, 633, 797
  toxic effects, 410, 569
Therapeutic alternatives, *definition*, 64
Therapeutic equivalent, *definition*, 64
Therapeutic orphans. *See* Orphan drugs.
Therapeutic substitution, *definition*, 64
Thiazide diuretics, 373, 374, 376
Third class of drugs, 9, 87, 184–187, 768
  See also Prescription-nonprescription (Rx-OTC) switch.
Third-party programs, APhA initiative on, 398, 401, 496
  reimbursement under. *See* Reimbursement.
Thomas, Joseph, III, "How to Select your Pharmacy's Legal Form of Organization, 838–842
Thomas, Lewis, 62
Thompson, Cindy L., 568
Thonzylamine, 738
Throat cultures, 66
Thromboxane, 614
Thyrotropin-releasing hormone, 611
Thyroxine, 252
Timed-release drug delivery systems. *See* Controlled-release drug delivery systems.
Timolol maleate, 374, 376
Tinnitus, 479
Titanium dioxide, 363
Tobramycin, 125, 778
Toffler, Alvin, 39
Tolazamide, 364, 778–789, 824–837
Tolbutamide, 364, 415, 824–837
Toledo-Pereyra, Luis, 801
Tolmetin, 13, 479
Tomkiewicz, J., 216
Toothpastes, 585
  See also Oral hygiene products.
Topical analgesics, 8
Topical antifungals, 126, 128, 660
Topical products, sales data, 499
Topical steroids, 8, 363
Torrico, Susan, 451
Tourette syndrome, 719
Toxic shock syndrome, 180, 576
Toxicology, 92–96
Transcutaneous stimulation (TCS), 299
Transdermal drug delivery systems, 614, 650, 740, 806
Transdermal nitroglycerin, 338, 412, 569, 614
Transmucosal drug delivery systems, 615–617
Transplants, bone marrow, 613
  islet cell, 801
  kidney, 129–130
Triamterene, 374, 376, 408
Triazolam, 12, 134–135, 587
Trichlormethiazide, 374
Tricyclic antidepressants, 511–514
Trimble, Michael, 196
Trimethadione, 200
Trimethoprim, 364, 408, 506
Troleandomycin, 288
Troupin, A.S., 202
Tuaminoheptane, 736
Tube feeding, 600
Tubocurarine, 136
Tyrosine, 806

U

Ulcers, 137–138, 614, 778–779
Ulene, Art, 74, 75
Ultraviolet light, sensitivity to, 362–366
Unipolar mood disorder, 511–514
United States Pharmacopeial convention, 763
Urinary citrate, 510
Urinary incontinence, 351–360
Urinary tract infections, 128–129
Urokinase, 122

V

Vaginal contraceptive sponges, 140, 180
Vaginal yeast infections, 8
Valentine, E. Michelle, 6, 109, 407, 443, 537
Valproic acid, 194, 199
Van Campen, Lynn, 438
Vane, John, 608, 614
Vann, James F., 768
  "Prescription Drug Abuse and Misuse: Primary Prevention Programs Are Needed," 493–495
Varicose veins, 658
Vasodilators, 374–377, 728
Veatch, R.M., 554
Venereal diseases. *See* Sexually-transmitted diseases.
Verapamil, 177, 338, 374, 377, 410, 778–789, 806
  disposable syringes, 403
Verhurst, Henry L., "The Pharmacist's Role in Toxicology," 92–96
Vessell, E.S., 793–794
Vickery, Donald, 790–792
Vidarabine, 140
Viral infections, 614–615, 734–740
Vitamin A, 344, 588
Vitamin B_6, 344
Vitamin B_{12}, 4–5
Vitamin C, 344, 588, 652
Vitamin D, 48, 344, 422
Vitamin E, 344, 405
Vitamin K, 104, 344, 759
Vitamin megadoses, 343–344, 350, 633
Vitamin-mineral combination, 806
Vitamins, cost data, 409
Voight, Jerry, 147
Voltz, Mary Louise, 729
Vordenbaumen, Timothy L., 6
Vorhauer, Bruce, 180

W

Wagner, Judith, 497
Waite, Wynn W., "The Pharmacist's Responsibility to Determine Limits to Prescribing Authority," 702–703
Waldman, R.J., 144
Ward, John R., 584
Warning labels for, aspirin, 142–143, 789
  contraceptives, 180
  controlled-release nitroglycerin, 797
  diet products, 416
  isotretinoin, 507
  nonprescription analgesics, 245
  oral antidiabetics, 415–416
  psychoactive drugs, 726
  sulfonamides, 506
  tampons, 576
Washington State Pharmacists Association, 805
Watkins, Edward E., Jr., 729
Watkins, L.R., 508
Watson, Dorothy P., 720
Waxman, Henry, 237–239, 328, 331, 398, 405, 502, 574, 636, 715, 788–789
Weaver, John C., 743, 746
Weaver, Warren E., "Pharmacy Education: The Twenty-First Century," 44–47
Weber, Michael, 650
Weight. *See* Body weight.
Weight control products. *See* Diet products.
Weikel, M. Keith, "Competition: Hallmark of Health Care in the Decades Ahead," 752–756
Weinberg, Marc, 800
Weinberger, Miles, 797
Weisbrod, Burt, 62
Weiss, Ted, 405
Weissman, Fred G., "Can I Afford a Computer?" 695–701
  "Will Your User-Friendly System Bite Your Hand After Six Months?" 689–694
Whall, Clifford, 335, 336
White, Eugene V., 76–84
White, Sara J., 70
Whitehead, Joe, 435
Williams, Joseph, 90, 638, 710
Williams, Ronald L., 240, 710, 776
  "Collaboration in High Blood Pressure control, 810–812
Wilson, J.T., 142
Wilson, Robert E., 329
Winawer, Sidney, 654
Windsor, R., 204
Wiser, Thomas H., "Remissive Therapy In Rheumatoid Arthritis," 482–486
Wolf, Harold H., 743, 750
Wolfe, Sidney, 174, 175
Wolfgang, Alan P., 329
Women, drug use by, 115, 408–410
Women in pharmacy, 214–219, 349, 397, 626–627, 660
Wong, Stewart, 13
Wood, Alistair, 577, 578
Woods, Leslie A., 233
Woods, William E., 639
World Health Organization, 250, 761
Wu, Wenhsien, 508
Wyden, Ron, 191

X

Xylometazoline, 736, 737

Y

Yarborough, Margaret C., 828
Yasgur, Jay, "On Homeopathy: A Modern-Day Perspective," 780–783
Yohimbine, 722
You, K., 144
Young, Frank E., 402, 573, 710, 789
Young, Ronald A., 233

Z

Zaenger, Allan, 603, 605
Zinc oxide, 363
Zirconium, 8
Zografi, George, 438
Zollinger-Ellison syndrome, 137–138
Zomepirac, 410, 714
Zuckerman, Ilene, 148